Alan Meds vs bmiMD
Two flat $99 injections separated mainly by how many states each will ship to.
Alan Meds
Editorial
$99/mo
Three compounded lines, each carrying a published figure. Semaglutide is $99 by injection and $135 as an oral, and tirzepatide is $145 by injection. Alan Meds states the rate holds at every dose rather than rising through the escalation, which is the part of a GLP-1 bill a buyer cannot see before enrolling. No compounding pharmacy is named. Coverage is stated across 46 states.
Pick it for: Buyers who also want an oral and a tirzepatide line priced
bmiMD
Editorial
$99/mo
Compounded semaglutide and compounded tirzepatide, both sold as microdose lines and both priced flat across doses. The $99 semaglutide rate is the twelve-month tier; a single month is $129. Each product page strikes a higher figure through and labels it a limited time offer, without dating it.
Pick it for: Buyers in a state Alan Meds does not reach
Our verdict
Both publish $99 and both state the rate holds at every dose. Alan Meds covers 46 states and BMIMD covers 50, so for four states the choice is made for you. Where they genuinely part company is depth: Alan Meds prices three lines, adding an oral at $135 and a tirzepatide injection at $145, while BMIMD prices two. A buyer who may switch molecule or format later is choosing a menu, not just a rate.
What actually separates them
Alan Meds and bmiMD state different things about where you can use it. Everything else they publish, they publish the same way.
Both are priced at the same figure, so the decision rests on everything else on this page.
Over twelve months both come to about $1,188, so the year is not what separates them.
| Alan Meds | bmiMD | |
|---|---|---|
| Where you can use it | 46 states | 50 states |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.